| Document Date: 2010-04-29 15:45:07
Open Document File Size: 258,14 KBShare Result on Facebook
City New York / Philadelphia / / Company IgG / Variant AB / McGraw-Hill / Mayo Medical Laboratories / GM2 Gangliosidosis Variant AB / Carrier / Tay-Sachs Variant AB / / Country United States / / Currency pence / / / Event FDA Phase / / IndustryTerm treatment of depression / timely processing / splice donor site / individual mail systems / / MedicalCondition myoclonic jerks / HIV / GM2 gangliosidoses / Tay-Sachs Disease Variant B1 / Diagnosis The GM2 gangliosidoses / GM2 Gangliosidoses TSD / muscle weakness / hepatitis B / Activator Deficiency / adult-onset GM2 gangliosidosis / Summary The GM2 gangliosidoses / gangliosidosis / milder / chronic clinical course / severe disease / paranoia / TaySachs Disease / ataxia / normal ganglion / lysosomal storage disorder / schizophrenia / disease / active site dysfunction / Tay-Sachs Disease / clinically devastating disorders / GM2 activator deficiency / substrates Mayo Test Report Variant Clinical Phenotype HEXB Mutation Mutation Mutation Deficiency / HCV / Sandhoff disease / biochemically distinguishable GM2 gangliosidosis / Inherited Disease / Lecithin Cholesterol Acyltransferase Deficiency / involuntary movements / β-subunit Deficiency / GM2 gangliosidosis / vegetative state / metabolic disease / involuntary shock / depression / juvenile-onset GM2 gangliosidosis / GM2 Gangliosidosis Variant B1 / autosomal recessive disease / / MedicalTreatment oral contraceptives / ovum donation / bone marrow transplant / counseling / enzyme replacement therapy / / Person Mayo Test / Mayo Tay-Sachs / Warren Tay / Bernard Sachs / / / Position WB / ordering physician / neurologist / genetic counselor / / Product glycine / GM2 / / ProvinceOrState Alberta / Louisiana / / RadioStation North Am 2002 / / Technology Antibodies / Genotyping / testing protocol / PDF / genotype / / URL http /
SocialTag |
July[removed]Communiqué A Volume 29